Drug intelligence / Profile preview

BX002-A

Development stage: Phase 1
Lead developer: BiomX, Inc.
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**BX002-A** is an orally administered, investigational bacteriophage cocktail developed by BiomX to selectively target *Klebsiella pneumoniae* in the gastrointestinal tract. It was evaluated in a randomized, single-blind, placebo-controlled Phase 1 study in healthy adults to assess safety, tolerability, and delivery of viable phages to stool; the broader development rationale was treatment of inflammatory bowel disease and primary sclerosing cholangitis associated with pro-inflammatory intestinal *K. pneumoniae*. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04737876))

Targets

Klebsiella pneumoniae cell-surface receptors

Beyond the preview

Go deeper on BX002-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BX002-A.

Explore the full profile